List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8517009/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	HipertensiÃ ³ n pulmonar en la enfermedad pulmonar intersticial. Archivos De Bronconeumologia, 2022, , .	0.8	0
2	External validation of the OPALS prediction model for in-hospital mortality in patients with acute decompensated pulmonary hypertension. ERJ Open Research, 2022, 8, 00006-2022.	2.6	1
3	Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension. Advances in Therapy, 2022, 39, 4374-4390.	2.9	2
4	Inhaled iloprost as third addâ \in on therapy in idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-3.	1.7	4
5	Electrical impedance tomography in pulmonary arterial hypertension. PLoS ONE, 2021, 16, e0248214.	2.5	6
6	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215.	27.0	224
7	Association between pulmonary artery to aorta diameter ratio with pulmonary hypertension and outcomes in diffuse cystic lung diseases. Medicine (United States), 2021, 100, e26483.	1.0	6
8	World Pulmonary Hypertension Day: reflections and planning. Jornal Brasileiro De Pneumologia, 2021, 47, e20210251.	0.7	2
9	Gas exchange: the neglected piece in the PAH puzzle. European Respiratory Journal, 2021, 58, 2101407.	6.7	0
10	Outcomes and prognostic factors of decompensated pulmonary hypertension in the intensive care unit. Respiratory Medicine, 2021, 190, 106685.	2.9	11
11	Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965.	0.8	26
12	Mechanisms of Exercise Limitation and Prevalence of Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis. Chest, 2020, 158, 2440-2448.	0.8	11
13	Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. PLoS ONE, 2020, 15, e0233063.	2.5	10
14	Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension. Clinics, 2020, 75, e1373.	1.5	3
15	Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Jornal Brasileiro De Pneumologia, 2020, 46, e20200204-e20200204.	0.7	3
16	The Brazilian Journal of Pulmonology and its progress in the major international databases. Jornal Brasileiro De Pneumologia, 2020, 46, e20200320-e20200320.	0.7	0
17	Loss of response to calcium channel blockers after long-term follow up in idiopathic pulmonary arterial hypertension. , 2020, , .		0
18	Extended anticoagulation after venous thromboembolism: should it be done?. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661987855.	2.6	9

#	Article	IF	CITATIONS
19	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005095.	2.2	8
20	Cancer-associated thrombosis: the when, how and why. European Respiratory Review, 2019, 28, 180119.	7.1	160
21	Clinical relevance of pulmonary vasculature involvement in sickle cell disease. British Journal of Haematology, 2019, 185, 317-326.	2.5	10
22	PROSTACYCLIN INTERNATIONAL EXPERT PANEL CONSENSUS-BASED RECOMMENDATIONS FOR THE USE OF SELEXIPAG IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Chest, 2019, 156, A1115-A1120.	0.8	0
23	The global view. Current Opinion in Pulmonary Medicine, 2019, 25, 391-397.	2.6	3
24	Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801913.	6.7	2,583
25	Platelets and chronic thromboembolic pulmonary hypertension. , 2019, , .		2
26	Platelets and pulmonary arterial hypertension (PAH). , 2019, , .		2
27	Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. Jornal Brasileiro De Pneumologia, 2019, 45, e20180297.	0.7	7
28	Pulmonary Hypertension in General Cardiology Practice. Arquivos Brasileiros De Cardiologia, 2019, 113, 419-428.	0.8	4
29	PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH). , 2019, , .		2
30	Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis: prevalence and the role of Cardiopulmonary Exercise Testing and echocardiogram in predicting it. , 2019, , .		0
31	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. European Respiratory Journal, 2018, 51, 1800307.	6.7	16
32	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. Journal of the American College of Cardiology, 2018, 71, 752-763.	2.8	82
33	RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study. Lung, 2018, 196, 157-164.	3.3	42
34	Building the Future of Trial Design in PAH on Solid Ground. Chest, 2018, 153, 1089-1090.	0.8	0
35	Prognostic relevance of appropriate renal function evaluation in pulmonary arterial hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 692-693.	0.6	1
36	Estimation of Stroke Volume and Stroke Volume Changes by Electrical Impedance Tomography. Anesthesia and Analgesia, 2018, 126, 102-110.	2.2	16

#	Article	IF	CITATIONS
37	Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. Clinics, 2018, 73, e216.	1.5	19
38	Unusual cause of wheezing: extrinsic bronchial compression by pulmonary artery aneurysm. European Journal of Cardio-thoracic Surgery, 2018, 54, 965-965.	1.4	1
39	Reperfusion in acute pulmonary thromboembolism. Jornal Brasileiro De Pneumologia, 2018, 44, 237-243.	0.7	9
40	Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. BMC Pulmonary Medicine, 2018, 18, 106.	2.0	21
41	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. PLoS ONE, 2018, 13, e0193226.	2.5	33
42	The need for a balance between highly prevalent diseases and neglected diseases. Jornal Brasileiro De Pneumologia, 2018, 44, 445-446.	0.7	1
43	Survival of connective tissue disease associated pulmonary arterial hypertension. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 186.	0.8	1
44	Pulmonary Hypertension: Definition, Classification, and Diagnosis. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 561-570.	2.1	7
45	Challenging the concept of adding more drugs in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1701527.	6.7	7
46	Uncovering Small Secrets in Big Data Sets. Circulation Research, 2017, 121, 317-319.	4.5	3
47	Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. Orphanet Journal of Rare Diseases, 2017, 12, 74.	2.7	34
48	Macitentan Improves Health-Related QualityÂof Life for Patients With Pulmonary Arterial Hypertension. Chest, 2017, 151, 106-118.	0.8	46
49	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 2017, 38, 1147-1155.	2.2	65
50	3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY. Arquivos Brasileiros De Cardiologia, 2017, 109, 1-104.	0.8	21
51	JBP and bibliometric Ândices. Jornal Brasileiro De Pneumologia, 2017, 43, 247-248.	0.7	3
52	Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies. , 2017, , .		0
53	Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL. , 2017, , .		0
54	Exercise in patients with pulmonary Langerhans cell histiocytosis: performance and mechanisms of limitation. , 2017, , .		0

#	Article	IF	CITATIONS
55	The use of new anticoagulants in CTEPH. , 2017, , .		Ο
56	Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension. , 2017, , .		0
57	Momentum. Jornal Brasileiro De Pneumologia, 2017, 43, 327-328.	0.7	Ο
58	New anticoagulants for the treatment of venous thromboembolism. Jornal Brasileiro De Pneumologia, 2016, 42, 146-154.	0.7	27
59	Respiratory therapy: a problem among children and adolescents with cystic fibrosis. Jornal Brasileiro De Pneumologia, 2016, 42, 29-34.	0.7	8
60	Pulmonary arterial hypertension in schistosomiasis. Current Opinion in Pulmonary Medicine, 2016, 22, 408-414.	2.6	20
61	Exercise Capacity Long-Term after Arterial Switch Operation for Transposition of the Great Arteries. Congenital Heart Disease, 2016, 11, 155-159.	0.2	12
62	A global view of pulmonary hypertension. Lancet Respiratory Medicine,the, 2016, 4, 306-322.	10.7	523
63	Consolidating in the present, with an eye to the future. Jornal Brasileiro De Pneumologia, 2016, 42, 399-400.	0.7	3
64	2016 - a second step. Jornal Brasileiro De Pneumologia, 2016, 42, 5-6.	0.7	2
65	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European Respiratory Journal, 2015, 46, 1711-1720.	6.7	39
66	Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. BMC Pulmonary Medicine, 2015, 15, 118.	2.0	16
67	Pulmonary hypertension in sickle cell disease. Current Opinion in Pulmonary Medicine, 2015, 21, 432-437.	2.6	8
68	Pulmonary Arterial Hypertension in the Southern Hemisphere. Chest, 2015, 147, 495-501.	0.8	54
69	What is new about Rio?. European Respiratory Journal, 2015, 45, 1211-1213.	6.7	2
70	Usefulness of Cardiovascular Magnetic Resonance IndicesÂto Rule In or Rule Out Precapillary Pulmonary Hypertension. Canadian Journal of Cardiology, 2015, 31, 1469-1476.	1.7	10
71	Epidemiology and Disease Classification of Pulmonary Hypertension. Respiratory Medicine, 2015, , 21-35.	0.1	1
72	Biomarkers and Prognostic Indicators in Pulmonary Arterial Hypertension. Current Hypertension Reports, 2015, 17, 556.	3.5	8

#	Article	IF	CITATIONS
73	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 405-413.	6.7	184
74	Management of Pulmonary ArterialÂHypertension. Journal of the American College of Cardiology, 2015, 65, 1976-1997.	2.8	296
75	Effect of Macitentan on Hospitalizations. JACC: Heart Failure, 2015, 3, 1-8.	4.1	51
76	Incidence of spontaneous subdural hematoma in incident cases of pulmonary arterial hypertension: a registry of cases occurring over a five-year period. Jornal Brasileiro De Pneumologia, 2015, 41, 101-102.	0.7	3
77	2015-another step along the road in a 40-year journey Jornal Brasileiro De Pneumologia, 2015, 41, 01-02.	0.7	10
78	Bringing the JBP and its readers closer together. Jornal Brasileiro De Pneumologia, 2015, 41, 209-210.	0.7	0
79	Capillary–hemangiomatosis like lesions in the lungs of sickle cell anemia patients. , 2015, , .		0
80	Prognostic value of predicted 6MWD in PAH. , 2015, , .		0
81	The next 40 years. Jornal Brasileiro De Pneumologia, 2015, 41, 404-404.	0.7	1
82	Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats. Jornal Brasileiro De Pneumologia, 2014, 40, 421-424.	0.7	13
83	Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension. Jornal Brasileiro De Pneumologia, 2014, 40, 609-616.	0.7	18
84	Brazilian Journal of Pulmonology and Portuguese Journal of Pulmonology: Strengthening ties in respiratory science. Revista Portuguesa De Pneumologia, 2014, 20, 285-286.	0.7	4
85	Quality of life as a prognostic marker in pulmonary arterial hypertension. Health and Quality of Life Outcomes, 2014, 12, 130.	2.4	40
86	Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension. European Respiratory Journal, 2014, 43, 963-965.	6.7	8
87	Goal-oriented treatment of pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine, 2014, 20, 409-413.	2.6	3
88	Reply. Journal of the American College of Cardiology, 2014, 63, 2882-2883.	2.8	3
89	Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. Journal of Infection, 2014, 68, 90-98.	3.3	33
90	Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study. Chest, 2014, 146, 860A.	0.8	13

#	Article	IF	CITATIONS
91	Skeletal Muscle Abnormalities in Pulmonary Arterial Hypertension. PLoS ONE, 2014, 9, e114101.	2.5	41
92	New steps for the international consolidation of the Brazilian Journal of Pulmonology. Jornal Brasileiro De Pneumologia, 2014, 40, 325-326.	0.7	5
93	Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case Report. Arquivos Brasileiros De Cardiologia, 2014, 102, e27-30.	0.8	2
94	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	27.0	1,168
95	Prevalence of Dyslipidemia in Children with Congenital Heart Disease. Arquivos Brasileiros De Cardiologia, 2013, 101, 273-6.	0.8	4
96	Idiopathic Pulmonary Arterial Hypertension. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 560-567.	2.1	11
97	Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. Chest, 2013, 144, 876A.	0.8	3
98	Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan. Chest, 2013, 144, 870B.	0.8	0
99	Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. Chest, 2013, 144, 879A.	0.8	1
100	Delayed Myocardial Enhancement by Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: A Marker of Severity of Disease. Arquivos Brasileiros De Cardiologia, 2013, 101, 377-8.	0.8	3
101	Pulmonary arterial hypertension: bridging the present to the future. European Respiratory Review, 2012, 21, 267-270.	7.1	12
102	Biomarkers in Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 59-64.	0.1	0
103	The Role of Target Therapies in Schistosomiasis-Associated Pulmonary Arterial Hypertension. Chest, 2012, 141, 923-928.	0.8	48
104	Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. European Respiratory Journal, 2012, 39, 112-118.	6.7	225
105	Safety and efficacy of sitaxsentan 50 and 100Âmg in patients with pulmonary arterial hypertension. Pulmonary Pharmacology and Therapeutics, 2012, 25, 33-39.	2.6	32
106	Cardiac Magnetic Resonance Imaging: What Can It Add to Our Knowledge of the Right Ventricle in Pulmonary Arterial Hypertension?. American Journal of Cardiology, 2012, 110, S25-S31.	1.6	61
107	Schistosomiasis and Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 143-148.	0.1	2
108	Comparação de dois modelos experimentais de hipertensão pulmonar. Jornal Brasileiro De Pneumologia, 2012, 38, 452-460.	0.7	6

#	Article	IF	CITATIONS
109	Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. European Respiratory Journal, 2011, 37, 813-822.	6.7	85
110	The Role Of Target-Therapies In Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , .		0
111	Comparative Analysis Of The Immunopathology In Idiopathic Versus Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , .		Ο
112	Correcting For Age And Sex Unmasks Decreased Right Ventricular Ejection Fraction In Pulmonary Hypertension. , 2011, , .		1
113	The Angle Between The Interventricular Septum And The Left Ventricular Free Wall As A New Index Of Right Ventricular Overload In Pulmonary Hypertension Patients: A Cardiac Magnetic Resonance Study. , 2011, , .		1
114	O papel dos exames de imagem na avaliação da circulação pulmonar. Jornal Brasileiro De Pneumologia, 2011, 37, 389-403.	0.7	5
115	Schistosomiasis and pulmonary hypertension. Expert Review of Respiratory Medicine, 2011, 5, 675-681.	2.5	27
116	Predicting Survival in Pulmonary Arterial Hypertension. Chest, 2011, 139, 1263-1264.	0.8	9
117	Letter by Montani et al Regarding Article, "Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension― Circulation, 2011, 123, e614; author reply e615.	1.6	7
118	Schistosomiasis and others in group 5. , 2011, , 491-499.		0
119	Schistosomiasis associated pulmonary hypertension. International Journal of Clinical Practice, 2010, 64, 25-28.	1.7	27
120	Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension. Journal of Receptor, Ligand and Channel Research, 2010, , 113.	0.7	1
121	Diagnóstico e tratamento da hipertensão pulmonar: uma atualização. Jornal Brasileiro De Pneumologia, 2010, 36, 795-811.	0.7	26
122	Letter by Dias et al Regarding Article, "Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy― Circulation, 2010, 122, e1.	1.6	1
123	Contemporary issues in pulmonary hypertension. European Respiratory Review, 2010, 19, 266-271.	7.1	12
124	Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 35, 1286-1293.	6.7	226
125	Predicting survival in pulmonary arterial hypertension: time to move forward. European Respiratory Journal, 2010, 35, 958-959.	6.7	4
126	Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. European Respiratory Journal, 2010, 36, 549-555.	6.7	582

#	Article	IF	CITATIONS
127	S152 Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression. Thorax, 2010, 65, A68-A69.	5.6	0
128	Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2010, 56, 715-720.	2.8	68
129	Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era. Circulation, 2010, 122, 156-163.	1.6	1,264
130	Validação de um protocolo para o teste de caminhada de seis minutos em esteira para avaliação de pacientes com hipertensão arterial pulmonar. Jornal Brasileiro De Pneumologia, 2009, 35, 423-430.	0.7	29
131	Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. Circulation, 2009, 119, 1518-1523.	1.6	176
132	Other Causes of PAH (Schistosomiasis, Porto-Pulmonary Hypertension and Hemolysis-Associated) Tj ETQq0 0 0	rgBT /Over 2.1	lock 10 Tf 50
133	Trends in pulmonary arterial hypertension. European Respiratory Review, 2009, 18, 7-12.	7.1	25
134	Pneumomediastinum after sneezing. Thorax, 2009, 64, 1104-1104.	5.6	4
135	Automatic versus manual pressure support reduction in the weaning of post-operative patients: a randomized controlled trial. Critical Care, 2009, 13, R6.	5.8	22
136	Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S85-S96.	2.8	353
137	Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S43-S54.	2.8	1,919
138	Corticoide sistêmico como tratamento de primeira linha da hipertensão pulmonar secundária a sÃndrome POEMS. Jornal Brasileiro De Pneumologia, 2009, 35, 804-808.	0.7	9
139	Evaluating humidity recovery efficiency of currently available heat and moisture exchangers: a respiratory system model study. Clinics, 2009, 64, 585-590.	1.5	18
140	Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 81-88.	5.6	405
141	Aortopulmonary Window: A Rare Cause of Pulmonary Hypertension. Respiration, 2008, 76, 351-352.	2.6	1
142	To the Editors. European Respiratory Journal, 2008, 33, 449-450.	6.7	0
143	Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. European Respiratory Journal, 2008, 31, 343-348.	6.7	118
144	Assessment of compliance in pulmonary arterial hypertension. European Heart Journal, 2008, 29, 1603-1604.	2.2	10

#	Article	IF	CITATIONS
145	Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of <i>BMPR2</i> Mutation. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1377-1383.	5.6	269
146	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	5.6	220
147	Doença veno-oclusiva pulmonar: alternativas diagnósticas e terapêuticas. Jornal Brasileiro De Pneumologia, 2008, 34, 749-752.	0.7	12
148	Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. European Respiratory Journal, 2007, 29, 462-468.	6.7	162
149	Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study. European Respiratory Journal, 2007, 29, 476-481.	6.7	87
150	Endothelin-1/Endothelin-3 Ratio. Chest, 2007, 131, 101-108.	0.8	64
151	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respiratory Medicine, 2007, 101, 69-75.	2.9	65
152	Functional implications of BAL in the presence of restrictive or obstructive lung disease. Respiratory Medicine, 2007, 101, 1344-1349.	2.9	0
153	Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Heart and Lung Transplantation, 2007, 26, 357-362.	0.6	126
154	Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. European Respiratory Journal, 2007, 29, 937-943.	6.7	143
155	Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. International Journal of Clinical Practice, 2007, 61, 153-156.	1.7	13
156	Systemic sclerosis and bone loss: the role of the disease and body composition. Scandinavian Journal of Rheumatology, 2006, 35, 384-387.	1.1	65
157	The effect of massive weight loss on pulmonary function of morbid obese patients. Respiratory Medicine, 2006, 100, 1100-1104.	2.9	41
158	Impacto de biópsia pulmonar a céu aberto na insuficiência respiratória aguda refratária. Jornal Brasileiro De Pneumologia, 2006, 32, 418-423.	0.7	15
159	Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática. Arquivos Brasileiros De Cardiologia, 2006, 87, e195-e197.	0.8	12
160	The Role of NT-proBNP as a Prognostic Marker in Pulmonary Hypertension. Chest, 2006, 130, 1627.	0.8	6
161	The Need for National Registries in Rare Diseases. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 228-228.	5.6	9
162	Long term imatinib treatment in pulmonary arterial hypertension. Thorax, 2006, 61, 736-736.	5.6	144

#	Article	IF	CITATIONS
163	Impact of open lung biopsy on refractory acute respiratory failure . Jornal Brasileiro De Pneumologia, 2006, 32, .	0.7	0
164	Impact of open lung biopsy on refractory acute respiratory failure. Jornal Brasileiro De Pneumologia, 2006, 32, 418-23.	0.7	6
165	Pulmonary arterial hypertension in ANCA-associated vasculitis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2006, 23, 223-8.	0.2	22
166	Acute vasodilator test in pulmonary arterial hypertension: Evaluation of two response criteria. Vascular Pharmacology, 2005, 43, 143-147.	2.1	40
167	Comparison of two flow generators with a noninvasive ventilator to deliver continuous positive airway pressure: a test lung study. Intensive Care Medicine, 2005, 31, 1587-1592.	8.2	19
168	Heterogeneous Remodeling of Lung Vessels in Idiopathic Pulmonary Fibrosis. Lung, 2005, 183, 291-300.	3.3	35
169	Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease. Journal of Inherited Metabolic Disease, 2005, 28, 603-605.	3.6	11
170	Ação da adenosina na circulação pulmonar de pacientes com hipertensão pulmonar primária. Jornal Brasileiro De Pneumologia, 2005, 31, 20-24.	0.7	2
171	N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension. European Respiratory Journal, 2005, 25, 509-513.	6.7	57
172	Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Current Medical Research and Opinion, 2005, 21, 907-911.	1.9	36
173	Pulmonary capillary pressure in pulmonary hypertension. Critical Care, 2005, 9, R132.	5.8	18
174	Evaluation of resistance in 8 different heat-and-moisture exchangers: effects of saturation and flow rate/profile. Respiratory Care, 2005, 50, 636-43.	1.6	20
175	Lesão por inalação de fumaça. Jornal Brasileiro De Pneumologia, 2004, 30, 557-565.	0.7	15
176	Tromboendarterectomia pulmonar em paciente com 80 anos de idade. Jornal Brasileiro De Pneumologia, 2004, 30, 485-487.	0.7	4
177	Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil. Revista Do Hospital Das Clinicas, 2002, 57, 167-174.	0.5	9
178	Mask mechanics and leak dynamics during noninvasive pressure support ventilation: a bench study. Intensive Care Medicine, 2001, 27, 1887-1891.	8.2	103